Rodríguez-Gutiérrez René, Montes-Villarreal Juan, Rodríguez-Velver Karla Victoria, González-Velázquez Camilo, Salcido-Montenegro Alejandro, Elizondo-Plazas Anasofia, González-González José Gerardo
Knowledge and Evaluation Research Unit in Endocrinology, Department of Medicine, Mayo Clinic, Rochester, Minnesota; Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Division of Endocrinology, Internal Medicine Department, University Hospital "Dr. José E. González", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico.
Am J Med Sci. 2017 Aug;354(2):165-171. doi: 10.1016/j.amjms.2017.04.010. Epub 2017 Jul 8.
Current evidence linking vitamin B12 deficiency with metformin use is inconsistent. Hence, there is uncertainty regarding the diagnostic approach in this scenario. Furthermore, this possible association has not been studied in the complete spectrum of patients with diabetes.
We conducted a cross-sectional, controlled study with the objective of assessing differences in serum vitamin B12 levels among patients with and without diabetes with different metformin-treatment regimens. A total of 150 participants were recruited: patients with diabetes (group 1: metformin alone ≥850mg/day, group 2: patients with type 2 diabetes naive to treatment and group 3: metformin ≥850mg/day, in addition to any other oral glucose lowering agent or insulin, or both) and without diabetes (group 4: polycystic ovary syndrome or group 5: healthy individuals). Serum vitamin B12, folate levels and complete blood counts were obtained for the entire population. Methylmalonic acid and homocysteine were obtained for patients when vitamin B12 levels were found to be borderline or low.
When patients with or without diabetes were compared, no significant difference was found in relation to their vitamin B12 levels (517.62 versus 433.83; P = 0.072). No difference in vitamin B12 levels was found among participants with metformin use and metformin naive participants (503.4 versus 462.3; P = 0.380).
Irrespective of metformin use, no significant difference in the serum levels of vitamin B12 was observed, both in patients with and without diabetes. In the light of the body of evidence and the results of this study, a universal recommendation for vitamin B12 deficiency screening cannot be made.
目前将维生素B12缺乏与使用二甲双胍联系起来的证据并不一致。因此,在这种情况下的诊断方法存在不确定性。此外,尚未在所有糖尿病患者中研究这种可能的关联。
我们进行了一项横断面对照研究,目的是评估不同二甲双胍治疗方案的糖尿病患者和非糖尿病患者血清维生素B12水平的差异。共招募了150名参与者:糖尿病患者(第1组:单独使用二甲双胍≥850mg/天,第2组:初治2型糖尿病患者,第3组:除任何其他口服降糖药或胰岛素或两者外,二甲双胍≥850mg/天)和非糖尿病患者(第4组:多囊卵巢综合征患者或第5组:健康个体)。对整个人群进行血清维生素B12、叶酸水平和全血细胞计数检测。当发现维生素B12水平处于临界值或偏低时,对患者进行甲基丙二酸和同型半胱氨酸检测。
比较有糖尿病和无糖尿病的患者时,发现他们的维生素B12水平无显著差异(517.62对433.83;P = 0.072)。使用二甲双胍的参与者和未使用二甲双胍的参与者之间维生素B12水平无差异(503.4对462.3;P = 0.380)。
无论是否使用二甲双胍,糖尿病患者和非糖尿病患者的血清维生素B12水平均无显著差异。鉴于现有证据和本研究结果,无法做出关于维生素B12缺乏筛查的通用建议。